Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$269.1M
57M shares
52-week range
$2.77 – $15.55
18% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
www.embecta.comNo one on the platform currently holds EMBC.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 144,287 | $1.3M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-08-27 | $0.0100 | 2026-09-15 |
| 2026-05-28 | $0.0100 | 2026-06-15 |
| 2026-02-27 | $0.1500 | 2026-03-17 |
| 2025-12-05 | $0.1500 | 2025-12-18 |
| 2025-08-29 | $0.1500 | 2025-09-15 |
| 2025-05-28 | $0.1500 | 2025-06-13 |
| 2025-02-28 | $0.1500 | 2025-03-14 |
| 2024-12-06 | $0.1500 | 2024-12-18 |
| 2024-08-27 | $0.1500 | 2024-09-13 |
| 2024-05-24 | $0.1500 | 2024-06-14 |
No one on the platform has traded EMBC yet.
| 2024-02-27 | $0.1500 | 2024-03-15 |
| 2023-12-01 | $0.1500 | 2023-12-15 |
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.0B | -5.6% | $1.59 | $1.55–$1.62 | 3.2× | 3 |
| 2027 | $1.1B | +6.1% | $1.74 | $1.73–$1.75 | 3.0× | 3 |
| 2028 | $1.1B | +0.8% | $1.93 | $1.42–$2.39 | 2.7× | 3 |
| 2029 | $1.1B | -0.2% | $2.96 | $2.95–$2.97 | 1.7× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-07 | $0.27 | $0.56 | +110.7% |
| 2026-05-05 | $0.42 | $0.27 | -35.7% |
| 2026-02-05 | $0.67 | $0.71 | +6.0% |
| 2025-11-25 | $0.70 | $0.50 | -28.6% |
| 2025-08-08 | $0.46 | $1.12 | +146.2% |
| 2025-05-09 | $0.66 | $0.70 | +6.1% |
| 2025-02-06 | $0.45 | $0.65 | +44.4% |
| 2024-11-26 | $0.36 |
| $0.45 |
| +25.0% |
| $524M |
| — |
| MRVIMaravai LifeSciences Holdings, Inc. | $5.78 | +0.00% | $1.6B | — |
| MYGNMyriad Genetics, Inc. | $3.17 | -1.86% | $299M | — |
Source: Financial Modeling Prep · peers by sector/industry
$EMBC Why is this stock easily still going to return a 100% in 6 months? * Analysts dropped projected price due to the expected continued decline in domestic earnings and lack of market share for injectables (This was proven wrong through new signed contracts increased domestic earnings and identifying new revenue streams) * Sales, spending, and debt were worse coming into and through Q2 when the stock price exceeded 9 in 2026. * EPS in Q3 exceeded 2025 Q4 when stock prices pushed past 12 a share. * Q1 represented the highest hedge fund acquisitions in the last 2 years. * EMBC repurchased approximately 2.7 million shares in Q3 and should be expected to purchase approximately 1.6 million in Q4. * internal purchasing of shares shows a solid belief in longevity and earnings. Expectations that more contracts will be signed, Ownen Mumford will be delivering a cutting edge injectable, a move to GLP-1 contracts, an anticipated higher EPS in the 4th less available stocks in circulation.
View on StockTwits ↗Put ticker JUNS onto your watchlist right now! JUNS has only 770k shares outstanding and only 480k shares public float. Look at what SDOT / YXT / DFNS / AKAN did on similar share numbers recently! JUNS has a similar move coming - Added a big position for a squeeze. $TMDX $EMBC :@
View on StockTwits ↗$EMBC CEO purchased 30,000 shares at $4.70 for a total of $140,937. Kurdikar Devdatt now owns 804,919 shares. https://ceo-buys.com
View on StockTwits ↗$EMBC way too strong.. I think 6 might be near term support soon.
View on StockTwits ↗$EMBC I am personally betting big on Nimish. His track record at Sandoz was absolutely phenomenal. While the Q2 report showed a drop in US sales, I truly believe Nimish has what it takes to turn this around. He commands massive respect among CEOs and executives across Big Pharma and MedTech. I’m really looking forward to tracking the upcoming Q3 and Q4 earnings reports now. $EMBC
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.